Skip to main content
SpringerLink
Log in

Adalimumab: a guide to its use in plaque psoriasis

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

References

  1. Croom KF, McCormack PL. Adalimumab: in plaque psoriasis. Am J Clin Dermatol 2009; 10(1): 43–50

    Article  PubMed  Google Scholar 

  2. Humira® (adalimumab): US prescribing information. North Chicago (IL): Abbott Laboratories, 2009 Mar

  3. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFα rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol sci 2007 Nov; 48(2): 87–101

    Article  PubMed  CAS  Google Scholar 

  4. Gordon KB, Bonish BK, Patel T, et al. The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005 Nov; 153(5): 945–53

    Article  PubMed  CAS  Google Scholar 

  5. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008 Feb; 117(2): 244–79

    Article  PubMed  CAS  Google Scholar 

  6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 Jan; 58(1): 106–15

    Article  PubMed  Google Scholar 

  7. European Medicines Agency. Humira 40 mg solution for injection: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu [Accessed 2009 Mar 31]

  8. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 Feb 11; 158(3): 558–66

    Article  PubMed  CAS  Google Scholar 

  9. Menter A, Papp K, Leonardi C, et al. Consistency of adalimumab response across subgroups of patients with moderate to severe psoriasis: results of the REVEAL study [abstract no. O-11]. Br J Dermatol 2007 Jul; 157Suppl. 1: 5–6

    Google Scholar 

  10. Langley R, Vender R, Gu Y, et al. Similar responses with adalimumab therapy in patients with moderate versus severe psoriasis: subanalysis of multiple placebo-controlled trials [abstract no. P2653]. J Am Acad Dermatol 2008 Feb; 58Suppl. 2: AB128

    Google Scholar 

  11. Gordon K, Tyring S, Gu Y, et al. Psoriasis patients treated continuously with adalimumab: efficacy and safety results from months 12 to 18 [abstract no. P2654]. J Am Acad Dermatol 2008 Feb; 58Suppl. 2: AB129

    Google Scholar 

  12. Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007; 18(6): 341–50

    Article  PubMed  CAS  Google Scholar 

  13. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 Mar; 158(3): 549–57

    Article  PubMed  CAS  Google Scholar 

  14. Mrowietz U, Gu Y, Okun M, et al. Methotrexate-treated psoriasis patients transitioning to adalimumab: efficacy and safety outcomes [abstract no. P2609]. J Am Acad Dermatol 2008 Feb; 58Suppl. 2: AB120

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adalimumab: a guide to its use in plaque psoriasis. Drugs Ther. Perspect 25, 6–9 (2009). https://doi.org/10.2165/0042310-200925070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925070-00002

Search

Navigation